May 08, 2026 a 12:38 pm
PODD: Analysts Ratings - Insulet Corporation
Insulet Corporation, a key player in the insulin delivery systems market, has witnessed notable support from analysts with a significant number of "Buy" and "Strong Buy" ratings. The persistence of "Hold" recommendations suggests a careful optimism among analysts, reflecting both opportunities and inherent market challenges. This balance of ratings provides potential investors insight into the market's current sentiment towards PODD.
Historical Stock Grades
The latest data for Insulet Corporation (as of May 2026) shows a concentrated sentiment towards positive recommendations. The details are as follows:
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 15 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Recent trends indicate a slight adjustment in overall analyst sentiment towards Insulet Corporation. Notably, there has been:
- A decline in "Strong Buy" recommendations from earlier highs.
- An increase and stabilization in "Buy" ratings, indicating sustained confidence.
- A constant yet marginal presence of "Hold" ratings.
While sell-side opinions remain virtually nonexistent, the incremental rise in neutral stances suggests cautious optimism.
Percentage Trends
Analyzing percentage shifts over recent months reveals:
- Stable "Buy" recommendations at around 60% to 63% of total ratings.
- A notable reduction in "Strong Buy" share from 42% to approximately 20%.
- "Hold" ratings have remained steady, accounting for roughly 11% to 18% of all ratings.
- The consistency in "Buy" and "Strong Buy" signals ongoing market confidence, albeit with moderated exuberance.
This reflects a strategic pivot towards more restrained optimism, concentrating on sustainable growth prospects.
Latest Analyst Recommendations
Insights into recent analyst activities offer a picture of unchanged confidence in Insulet Corporation's stock:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-07 | Outperform | Outperform | RBC Capital |
| 2026-05-07 | Outperform | Outperform | Bernstein |
| 2026-05-07 | Outperform | Outperform | Evercore ISI Group |
| 2026-05-07 | Outperform | Outperform | Oppenheimer |
| 2026-05-07 | Overweight | Overweight | JP Morgan |
Analyst Recommendations with Change of Opinion
Notable changes among the analyst community highlight a cautious recalibration of expectations:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-24 | Neutral | Buy | Rothschild & Co |
| 2026-04-07 | Neutral | Buy | Citigroup |
| 2026-01-12 | Underweight | Equal Weight | Barclays |
| 2025-11-19 | Buy | Neutral | UBS |
| 2025-05-13 | Outperform | Peer Perform | Wolfe Research |
Interpretation
The analyst community's evaluation reflects a balanced view of Insulet Corporation, suggesting steady confidence with an undercurrent of caution in light of market conditions. Recent sentiment trends imply heightened scrutiny and a reluctance to overcommit, while stable ratings consolidation points to enduring market trust. This mixed yet hopeful outlook signifies a resilience amid potential market fluctuations.
Conclusion
In summary, Insulet Corporation's current market standing is bolstered by robust analyst support, particularly in "Buy" ratings, tempered by a careful anticipation of market dynamics. The diversity of opinions, including a shift towards neutrality, underscores the need for prudent investment strategies aligned with industry trends. The ongoing recalibration of ratings denotes an evolving landscape wherein opportunities coexist with calculated risks.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years